The US Food and Drug Administration has granted 510(k) clearance for a next-generation catheter-based coronary imaging system (LipiScan IVUS; InfraReDx Inc) to help clinicians detect and also characterize lipid core coronary plaques (LCPs).
Built on the company's original near-infrared (NIR) spectroscopy (LipiScan NIR) platform, the 1-step cardiac catheter incorporates intravascular ultrasonography (IVUS) technology to provide clinicians with a grayscale image of the coronary artery along with a complete and coregistered chemogram — a map of LCPs within the imaged vessel.